Full detail content for this treatment is being translated. For a localized consultation in English, please contact our coordinators — we respond within 24 hours.
Hasumi Cancer Vaccine (HITV)
Hasumi Immuno-Tumor Vaccine
A cancer-vaccine pioneer since 1948 — 70 years of experience with more than 200,000 patients worldwide and a 15-20% improvement in five-year post-surgery survival.
Years of clinical experience
Patients treated worldwide
Five-year post-surgery survival gain
Proprietary therapy pillars
Conventional Vaccines vs. Hasumi Autologous Vaccine
The Hasumi vaccine incorporates autologous antigens from the patient's own urine, mirroring each person's unique tumor profile more closely.
Conventional vaccines (foreign antigens) vs. autologous vaccines (patient's own urinary antigens)
Detailed overview of eligibility criteria and optimal treatment-start timing.
70 Years of the Hasumi Vaccine
From Dr. Kiichiro Hasumi's pioneering discovery in 1948 to today's personalized HITV therapy, the Hasumi vaccine has shaped cancer immunotherapy for 70 years.
Research by Dr. Kiichiro Hasumi
Development and first clinical use of the Hasumi vaccine based on the "cancer-virus" hypothesis.
Opening of the Shukoukai Clinic
The world's first clinic dedicated to cancer immunotherapy.
International Research Network
Joint research launched with the University of Maryland in the United States.
Modernization of HITV
Development of personalized HITV and preHITV therapies.
200,000 Patients Treated
More than 200,000 patients treated worldwide, continuously reinvigorating immunotherapy as the "fourth pillar" of cancer care.
The Three Pillars of Shukoukai Therapy
Hasumi Vaccine
The core traditional therapy: antigen panels tailored to the cancer type and stage are combined with immune-activating adjuvants to create a bespoke formula. Administered subcutaneously on a 5-days-on / 4-days-off rhythm.
HITV
A modern personalized vaccine built from the patient's own tumor antigens, precisely aligned with each individual's cancer profile. Indicated for advanced or recurrent disease.
preHITV
A perioperative formulation used before and after surgery to strengthen the immune system and help prevent recurrence. Combined with the Hasumi vaccine and HITV, it completes a full prevention-and-treatment platform.
Four common concerns — and honest answers
Specific answers depend on your medical record and your attending physician. We ensure language is not a barrier to your understanding.
Q1Will it hurt?
Pain depends on the person and the procedure. Japanese hospitals follow a complete pain-management workflow: pre-procedure assessment, intra-procedural anaesthesia, and post-procedural pain control. You can ask your attending physician about expected pain at the pre-procedure briefing — our interpreter will translate question and answer accurately.
Q2How serious are the side effects?
Side effects differ by therapy. Before you sign consent, Japanese hospitals will walk you through the possible side effects, their probability, and how they are managed. If anything is unclear, we will ask the physician to re-explain until you fully understand before signing.
Q3How long is the hospital stay?
It depends on the therapy. Day treatments require no admission; some therapies need 1–3 days of observation; surgery or particle therapy may need 1–3 weeks. Your physician will note the duration in the treatment plan, and we translate the plan for you and your family.
Q4How soon after treatment can I fly home?
Day treatments and outpatient therapies usually allow same-day or next-day flights. For therapies with hospitalisation, you typically observe for 2–3 days post-discharge, and your physician issues a fitness-to-fly note. We help you book a flexible return ticket.
This section is general guidance. Specific expectations, suitability, and timing must be determined by your attending physician in Japan based on your complete medical record.
Medical information disclaimer
The information on this page is for educational reference only and does not constitute medical advice. The suitability, side effects, and expected outcomes of any therapy must be determined by your attending physician in Japan based on your complete medical record. Medical Supporter does not replace any professional medical judgement.
Request a Hasumi Vaccine Consultation
From cancer prevention to post-surgical recurrence protection, the 70-year-old Hasumi vaccine offers a truly personalized immunotherapy pathway.